Hot Biotech Stocks To Watch Right Now: Celldex Therapeutics, Inc (CLDX), Heat Biologics, Inc. (HTBX)
By Tom Burr On March 25, 2016
Celldex Therapeutics, Inc. (CLDX) ended last trading session with a change of -1.12 percent. It trades at an average volume of 3.94M shares versus 2.4M shares recorded at the end of last trading session. The share price of $3.53 is at a distance of 19.26 percent from its 52-week low and down -88.34 percent versus its peak. The company has a market cap of $348.41M and currently has 98.70M shares outstanding. The share price is currently -28.83 percent versus its SMA20, -50.57 percent versus its SMA50, and -76.32 percent versus its SMA200. The stock has a weekly performance of 11.36 percent and is -77.49 percent year-to-date as of the recent close.
Celldex Therapeutics, Inc. (CLDX) on March 17, 2016 announced that the Company and its collaborating investigators will present seven posters with new clinical and preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.
Highlights include immune response data from the ongoing Phase 1/2 study of varlilumab and nivolumab in multiple solid tumors, the role of gpNMB as a relevant therapeutic target across multiple cancers and a late-breaking poster from the Phase 1 investigator-sponsored study of CDX-301 (Flt3L) in B-cell lymphomas.
The following Celldex-sponsored abstracts have been selected for poster presentations at AACR:
Title: Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse eventsDate/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 13
Abstract: CT023
Title: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcomaDate/Time: Wednesday, April 20, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 27
Abstract: 5032
Title: IHC and RT-PCR assays for detection of cancer antigen NY-ESO-1 in human tissuesDate/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 21
Abstract: 1373
Title: Development and characterization of novel CD40 antibody agonists for cancer immunotherapyDate/Time: Wednesday, April 20, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 22
Abstract: 4866
The following investigator-sponsored abstracts have been selected for poster presentations at AACR:
Title: In situ vaccination of low-grade lymphoma with intratumoral Flt3L and poly-ICLC with low-dose radiotherapyDate/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 10
Abstract: LB-081
Title: Targeting GPNMB with 89Zr-CR011 for PET imaging of triple negative breast cancerDate/Time: Tuesday, April 19, 1:00 p.m. – 5:00 p.m. CDT
Location: Section 33
Abstract: 4209
Title: Targeting the melanosome: overcoming MAPK-inhibitor resistance in melanomaDate/Time: Sunday, April 17, 1:00 p.m. – 5:00 p.m. CDT
Location: Section 16
Abstract: 296
Heat Biologics, Inc. (HTBX) recently recorded 2.59 percent change and currently at $0.72 is 12.2 percent away from its 52-week low and down -91.7 percent versus its peak. It has a past 5-day performance of -62.21 percent and trades at an average volume of 366.05K shares. The stock has a 1-month performance of -39.14 percent and is -70.57 percent year-to-date as of the recent close. There were about 8.41M shares outstanding which made its market cap $6.04M. The share price is currently -21.95 percent versus its SMA20, -57.41 percent versus its SMA50, and -81.57 percent versus its SMA200.
Heat Biologics, Inc. (HTBX) on March 23, 2016 announced the closing of its previously announced underwritten public offering of 9,100,000 shares of its common stock and warrants to purchase up to an aggregate of 6,825,000 shares of its common stock at a combined public offering price of $0.75 per share and related warrant. Each share of its common stock was sold together with a warrant to purchase 0.75 of a share of its common stock. The gross proceeds from this offering were approximately $6.8 million, before deducting the underwriting discount and estimated offering expenses payable by Heat, but excluding proceeds from the exercise of any warrants.
Heat intends to use the net proceeds from the offering to complete its Phase 2 clinical trial evaluating HS-410 for the treatment of non-muscle invasive bladder cancer (NMIBC), which remains Heat’s primary focus. The remaining net proceeds are expected to be used to advance the current eight patients enrolled in Heat’s Phase 1b clinical trial evaluating HS-110 for the treatment of non-small cell lung cancer (NSCLC) through the reporting of topline data, as well as for licensing or acquisition of assets complementary to its existing programs and for general corporate and working capital purposes.
By Tom Burr On March 25, 2016
Celldex Therapeutics, Inc. (CLDX) ended last trading session with a change of -1.12 percent. It trades at an average volume of 3.94M shares versus 2.4M shares recorded at the end of last trading session. The share price of $3.53 is at a distance of 19.26 percent from its 52-week low and down -88.34 percent versus its peak. The company has a market cap of $348.41M and currently has 98.70M shares outstanding. The share price is currently -28.83 percent versus its SMA20, -50.57 percent versus its SMA50, and -76.32 percent versus its SMA200. The stock has a weekly performance of 11.36 percent and is -77.49 percent year-to-date as of the recent close.
Celldex Therapeutics, Inc. (CLDX) on March 17, 2016 announced that the Company and its collaborating investigators will present seven posters with new clinical and preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.
Highlights include immune response data from the ongoing Phase 1/2 study of varlilumab and nivolumab in multiple solid tumors, the role of gpNMB as a relevant therapeutic target across multiple cancers and a late-breaking poster from the Phase 1 investigator-sponsored study of CDX-301 (Flt3L) in B-cell lymphomas.
The following Celldex-sponsored abstracts have been selected for poster presentations at AACR:
Title: Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse eventsDate/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 13
Abstract: CT023
Title: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcomaDate/Time: Wednesday, April 20, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 27
Abstract: 5032
Title: IHC and RT-PCR assays for detection of cancer antigen NY-ESO-1 in human tissuesDate/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 21
Abstract: 1373
Title: Development and characterization of novel CD40 antibody agonists for cancer immunotherapyDate/Time: Wednesday, April 20, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 22
Abstract: 4866
The following investigator-sponsored abstracts have been selected for poster presentations at AACR:
Title: In situ vaccination of low-grade lymphoma with intratumoral Flt3L and poly-ICLC with low-dose radiotherapyDate/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 10
Abstract: LB-081
Title: Targeting GPNMB with 89Zr-CR011 for PET imaging of triple negative breast cancerDate/Time: Tuesday, April 19, 1:00 p.m. – 5:00 p.m. CDT
Location: Section 33
Abstract: 4209
Title: Targeting the melanosome: overcoming MAPK-inhibitor resistance in melanomaDate/Time: Sunday, April 17, 1:00 p.m. – 5:00 p.m. CDT
Location: Section 16
Abstract: 296
Heat Biologics, Inc. (HTBX) recently recorded 2.59 percent change and currently at $0.72 is 12.2 percent away from its 52-week low and down -91.7 percent versus its peak. It has a past 5-day performance of -62.21 percent and trades at an average volume of 366.05K shares. The stock has a 1-month performance of -39.14 percent and is -70.57 percent year-to-date as of the recent close. There were about 8.41M shares outstanding which made its market cap $6.04M. The share price is currently -21.95 percent versus its SMA20, -57.41 percent versus its SMA50, and -81.57 percent versus its SMA200.
Heat Biologics, Inc. (HTBX) on March 23, 2016 announced the closing of its previously announced underwritten public offering of 9,100,000 shares of its common stock and warrants to purchase up to an aggregate of 6,825,000 shares of its common stock at a combined public offering price of $0.75 per share and related warrant. Each share of its common stock was sold together with a warrant to purchase 0.75 of a share of its common stock. The gross proceeds from this offering were approximately $6.8 million, before deducting the underwriting discount and estimated offering expenses payable by Heat, but excluding proceeds from the exercise of any warrants.
Heat intends to use the net proceeds from the offering to complete its Phase 2 clinical trial evaluating HS-410 for the treatment of non-muscle invasive bladder cancer (NMIBC), which remains Heat’s primary focus. The remaining net proceeds are expected to be used to advance the current eight patients enrolled in Heat’s Phase 1b clinical trial evaluating HS-110 for the treatment of non-small cell lung cancer (NSCLC) through the reporting of topline data, as well as for licensing or acquisition of assets complementary to its existing programs and for general corporate and working capital purposes.
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
